The field of adenovirology is undergoing rapid change in response to increasing appreciation of the potential advantages of adenoviruses as the basis for new vaccines and as vectors for gene and cancer therapy. Substantial knowledge and understanding of adenoviruses at a molecular level has made their manipulation for use as vaccines and therapeutics relatively straightforward in comparison with other viral vectors. In this review we summarize the structure and life cycle of the adenovirus and focus on the use of adenovirus-based vectors in vaccines against infectious diseases and cancers. Strategies to overcome the problem of preexisting antiadenovirus immunity, which can hamper the immunogenicity of adenovirus-based vaccines, are discussed. When armed with tumor-associated antigens, replication-deficient and oncolytic adenoviruses can efficiently activate an antitumor immune response. We present concepts on how to use adenoviruses as therapeutic cancer vaccines and consider some of the strategies used to further improve antitumor immune responses. Studies that explore the prospect of adenoviruses as vaccines against infectious diseases and cancer are underway, and here we give an overview of the latest developments.
Get full access to this article
View all access options for this article.
References
1.
AbbinkP., LemckertA.A., EwaldB.A., et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol., 81, 4654–4663.
2.
AbeS., OkudaK., UraT., et al. (2009). Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J. Gene Med., 11, 570–579.
3.
AlexanderJ., MendyJ., VangL., et al. (2013). Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. PLoS One, 8, e82380.
4.
Ambriovic-RistovA., MercierS., and EloitM. (2003). Shortening adenovirus type 5 fiber shaft decreases the efficiency of postbinding steps in CAR-expressing and nonexpressing cells. Virology, 312, 425–433.
5.
AmstutzB., GastaldelliM., KalinS., et al. (2008). Subversion of CtBP1-controlled macropinocytosis by human adenovirus serotype 3. EMBO J., 27, 956–969.
6.
AntrobusR.D., CoughlanL., BerthoudT.K., et al. (2013). Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol. Ther., 22, 668–674.
7.
ArnbergN. (2012). Adenovirus receptors: implications for targeting of viral vectors. Trends Pharmacol. Sci., 33, 442–448.
8.
AthappillyF.K., MuraliR., RuxJ.J., et al. (1994). The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution. J. Mol. Biol., 242, 430–455.
9.
BackerR., SchwandtT., GreuterM., et al. (2010). Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. Proc. Natl. Acad. Sci. USA, 107, 216–221.
10.
BadenL.R., WalshS.R., SeamanM.S., et al. (2013). First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J. Infect. Dis., 207, 240–247.
11.
BalandyaE., MillerA.D., BeckM., et al. (2014). Adenovirus serotype 26 and 35 vectors induce SIV-specific T lymphocyte responses in foreskin in Rhesus monkeys. J Virol., 88, 3756–3765.
12.
BarlanA.U., GriffinT.M., McguireK.A., and WiethoffC.M. (2011). Adenovirus membrane penetration activates the NLRP3 inflammasome. J. Virol., 85, 146–155.
13.
BarouchD.H. (2010). Novel adenovirus vector-based vaccines for HIV-1. Curr. Opin. HIV AIDS, 5, 386–390.
14.
BarouchD.H., KikS.V., WeverlingG.J., et al. (2011). International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine, 29, 5203–5209.
15.
BarouchD.H., LiuJ., PeterL., et al. (2013). Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J. Infect. Dis., 207, 248–256.
16.
Basner-TschakarjanE., GaffalE., O'keeffeM., et al. (2006). Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production. J. Gene Med., 8, 1300–1306.
17.
Bayo-PuxanN., CascalloM., GrosA., et al. (2006). Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J. Gen. Virol., 87, 2487–2495.
18.
BenlahrechA., HarrisJ., MeiserA., et al. (2009). Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl. Acad. Sci. USA, 106, 19940–19945.
19.
BergelsonJ.M., CunninghamJ.A., DroguettG., et al. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science, 275, 1320–1323.
20.
BortolanzaS., BunualesM., OtanoI., et al. (2009). Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol. Ther., 17, 614–622.
21.
BradleyR.R., LynchD.M., IampietroM.J., et al. (2012). Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J. Virol., 86, 625–629.
22.
BridgemanA., RoshormY., LockettL.J., et al. (2009). Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine, 28, 474–483.
23.
BristolJ.A., ZhuM., JiH., et al. (2003). In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol. Ther., 7, 755–764.
24.
BruderJ.T., SemenovaE., ChenP., et al. (2012). Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS One, 7, e33920.
25.
BruderJ.T., ChenP., SemenovaE., et al. (2013). Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors. J. Virol., 87, 9661–9671.
26.
BuchbinderS.P., MehrotraD.V., DuerrA., et al. (2008). Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, 372, 1881–1893.
27.
BurkeJ.M., LammD.L., MengM.V., et al. (2012). A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J. Urol., 188, 2391–2397.
28.
CalcedoR., VandenbergheL.H., RoyS., et al. (2009). Host immune responses to chronic adenovirus infections in human and nonhuman primates. J. Virol., 83, 2623–2631.
29.
CaponeS., Reyes-SandovalA., NaddeoM., et al. (2010). Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine, 29, 256–265.
30.
CervasiB., CarnathanD.G., SheehanK.M., et al. (2013). Immunological and virological analyses of rhesus macaques immunized with chimpanzee adenoviruses expressing the simian immunodeficiency virus Gag/Tat fusion protein and challenged intrarectally with repeated low doses of SIVmac. J. Virol., 87, 9420–9230.
31.
ChenL., and FliesD.B. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol., 13, 227–242.
32.
ChengC., GallJ.G., NasonM., et al. (2010). Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J. Virol., 84, 630–638.
33.
ChoH.I., KimH.J., OhS.T., and KimT.G. (2003). In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine, 22, 224–236.
34.
ChoiK.J., KimJ.H., LeeY.S., et al. (2006). Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther., 13, 1010–1020.
35.
ChuangI., SedegahM., CicatelliS., et al. (2013). DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One, 8, e55571.
36.
ColinM., MaillyL., RogeeS., and D'halluinJ.C. (2005). Efficient species C HAdV infectivity in plasmocytic cell lines using a clathrin-independent lipid raft/caveola endocytic route. Mol. Ther., 11, 224–236.
37.
CollocaS., BarnesE., FolgoriA., et al. (2012). Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med., 4, 115ra2.
38.
CoyneC.B., and BergelsonJ.M. (2005). CAR: a virus receptor within the tight junction. Adv. Drug Deliv. Rev., 57, 869–882.
39.
Crawford-MikszaL., and SchnurrD.P. (1996). Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol., 70, 1836–1844.
40.
CrociD.O., Zacarias FluckM.F., RicoM.J., et al. (2007). Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol. Immunother., 56, 1687–1700.
41.
DavisonE., DiazR.M., HartI.R., et al. (1997). Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. J. Virol., 71, 6204–6207.
42.
DavisonE., KirbyI., WhitehouseJ., et al. (2001). Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha(v)beta1 integrin and can be modulated by changes in beta1 integrin function. J. Gene Med., 3, 550–559.
43.
De GruijlT.D., and Van De VenR. (2012). Chapter 6: Adenovirus-based immunotherapy of cancer: promises to keep. In Advances in Cancer Research. DavidT.C. and PaulB.F., eds. (Academic Press, New York) pp 147–220.
44.
Del VecchioM., BajettaE., CanovaS., et al. (2007). Interleukin-12: biological properties and clinical application. Clin. Cancer Res., 13, 4677–4685.
45.
DiaconuI., CerulloV., HirvinenM.L.M., et al. (2012). Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res., 72, 2327–2338.
46.
DoroninK., FlattJ.W., Di PaoloN.C., et al. (2012). Coagulation factor X activates innate immunity to human species C adenovirus. Science, 338, 795–798.
47.
DraperS.J., BiswasS., SpencerA.J., et al. (2010). Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J. Immunol., 185, 7583–7595.
48.
DudarevaM., AndrewsL., GilbertS.C., et al. (2009). Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine, 27, 3501–3504.
49.
ElguetaR., BensonM.J., De VriesV.C., et al. (2009). Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev., 229, 152–172.
50.
EwerK.J., O'haraG.A., DuncanC.J., et al. (2013). Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun., 4, 2836.
51.
FallauxF.J., KranenburgO., CramerS.J., et al. (1996). Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther., 7, 215–222.
52.
FallauxF.J., BoutA., Van Der VeldeI., et al. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther., 9, 1909–1917.
53.
FejerG., DrechselL., LieseJ., et al. (2008). Key role of splenic myeloid DCs in the IFN-alphabeta response to adenoviruses in vivo. PLoS Pathog., 4, e1000208.
54.
FitzgeraldJ.C., GaoG.P., Reyes-SandovalA., et al. (2003). A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol., 170, 1416–1422.
55.
FranciszkiewiczK., BoissonnasA., BoutetM., et al. (2012). Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res., 72, 6325–6332.
56.
FuxeJ., LiuL., MalinS., et al. (2003). Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int. J. Cancer, 103, 723–729.
57.
GaggarA., ShayakhmetovD.M., and LieberA. (2003). CD46 is a cellular receptor for group B adenoviruses. Nat. Med., 9, 1408–1412.
58.
GaoW., SoloffA.C., LuX., et al. (2006). Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol., 80, 1959–1964.
59.
GastaldelliM., ImelliN., BouckeK., et al. (2008). Infectious adenovirus type 2 transport through early but not late endosomes. Traffic, 9, 2265–2278.
60.
GeisbertT.W., BaileyM., HensleyL., et al. (2011). Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol., 85, 4222–4233.
61.
GilliganM.G., KnoxP., WeedonS., et al. (1998). Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Ther., 5, 965–974.
62.
GrahamF.L., SmileyJ., RussellW.C., and NairnR. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36, 59–74.
63.
GrayG., BuchbinderS., and DuerrA. (2010). Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr. Opin. HIV AIDS, 5, 357–361.
64.
GurwithM., LockM., TaylorE.M., et al. (2013). Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect. Dis., 13, 238–250.
65.
HammerS.M., SobieszczykM.E., JanesH., et al. (2013). Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med., 369, 2083–2092.
66.
HanahanD., and WeinbergR.A. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646–674.
67.
HangalapuraB.N., OosterhoffD., GuptaT., et al. (2011). Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Vaccine, 29, 2313–2321.
68.
HaruiA., RothM.D., KiertscherS.M., et al. (2004). Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL. Gene Ther., 11, 1617–1626.
69.
HolstP.J., OrskovC., ThomsenA.R., and ChristensenJ.P. (2010). Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J. Immunol., 184, 4431–4439.
70.
HoltermanL., VogelsR., Van Der VlugtR., et al. (2004). Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J. Virol., 78, 13207–13215.
71.
HongS.S., HabibN.A., FranquevilleL., et al. (2003). Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J. Virol., 77, 10366–10375.
72.
HuangS., KamataT., TakadaY., et al. (1996). Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J. Virol., 70, 4502–4508.
73.
HuebnerR.J., RoweW.P., and LaneW.T. (1962). Oncogenic effects in hamsters of human adenovirus types 12 and 18. Proc. Natl. Acad. Sci. USA, 48, 2051–2058.
74.
Iacobelli-MartinezM., and NemerowG.R. (2007). Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J. Virol., 81, 1305–1312.
75.
JohanssonC., JonssonM., MarttilaM., et al. (2007). Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells. J. Virol., 81, 954–963.
76.
JohnsonM.J., PetrovasC., YamamotoT., et al. (2012). Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J. Immunol., 188, 6109–6118.
77.
KahlC.A., BonnellJ., HiriyannaS., et al. (2010). Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine, 28, 5691–5702.
78.
KalinS., AmstutzB., GastaldelliM., et al. (2010). Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35. J. Virol., 84, 5336–5350.
79.
KanervaA., NokisalmiP., DiaconuI., et al. (2013). Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin. Cancer Res., 19, 2734–2744.
80.
KaranD., DubeyS., Van VeldhuizenP., et al. (2011). Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Immunotherapy, 3, 735–746.
81.
KedlR.M., KapplerJ.W., and MarrackP. (2003). Epitope dominance, competition and T cell affinity maturation. Curr. Opin. Immunol., 15, 120–127.
82.
KeeferM.C., GilmourJ., HayesP., et al. (2012). A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One, 7, e41936.
83.
KrauseA., JohJ.H., HackettN.R., et al. (2006). Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J. Virol., 80, 5523–5530.
84.
KritzA.B., NicolC.G., DishartK.L., et al. (2007). Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Mol. Ther., 15, 741–749.
85.
KronM.W., EnglerT., SchmidtE., et al. (2011). High-capacity adenoviral vectors circumvent the limitations of DeltaE1 and DeltaE1/DeltaE3 adenovirus vectors to induce multispecific transgene product-directed CD8 T-cell responses. J. Gene Med., 13, 648–657.
86.
KuballJ., SchulerM., Antunes FerreiraE., et al. (2002). Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther., 9, 833–843.
87.
KurachiS., KoizumiN., SakuraiF., et al. (2007). Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein, I.X., or hexon. Gene Ther., 14, 266–274.
88.
LamE., SteinS., and Falck-PedersenE. (2014). Adenovirus detection by the cGAS/STING/TBK1 DNA sensing cascade. J. Virol., 88, 974–981.
89.
LambeT., CareyJ.B., LiY., et al. (2013). Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci. Rep., 3, 1443.
90.
LanziA., Ben YoussefG., PerricaudetM., and BenihoudK. (2011). Anti-adenovirus humoral responses influence on the efficacy of vaccines based on epitope display on adenovirus capsid. Vaccine, 29, 1463–1471.
91.
LaptevaN., and HuangX.F. (2010). CCL5 as an adjuvant for cancer immunotherapy. Exp. Opin. Biol. Ther., 10, 725–733.
92.
LaptevaN., AldrichM., WeksbergD., et al. (2009). Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J. Immunother., 32, 145–156.
93.
LeeY.-S., KimJ.-H., ChoiK.-J., et al. (2006). Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin. Cancer Res., 12, 5859–5868.
94.
LeenA.M., SiliU., VaninE.F., et al. (2004). Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood, 104, 2432–2440.
95.
LemckertA.A., SumidaS.M., HoltermanL., et al. (2005). Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J. Virol., 79, 9694–9701.
96.
LemckertA.A., GrimbergenJ., SmitsS., et al. (2006). Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J. Gen. Virol., 87, 2891–2899.
97.
LiH., RheeE.G., Masek-HammermanK., et al. (2012). Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J. Virol., 86, 10862–10865.
98.
LiuH., JinL., KohS.B., et al. (2010). Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks. Science, 329, 1038–1043.
99.
LiuJ., LiH., IampietroM.J., and BarouchD.H. (2012). Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys. J. Virol., 86, 7829–7835.
100.
LotemM., ZhaoY., RileyJ., et al. (2006). Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J. Immunother., 29, 616–627.
LubaroffD.M., KonetyB.R., LinkB., et al. (2009). Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin. Cancer Res., 15, 7375–7380.
103.
MadischI., HarsteG., PommerH., and HeimA. (2005). Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy. J. Virol., 79, 15265–15276.
104.
MastT.C., KiersteadL., GuptaS.B., et al. (2010). International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine, 28, 950–957.
105.
McCoyK., TatsisN., Korioth-SchmitzB., et al. (2007). Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol., 81, 6594–6604.
106.
MooreM., HorikoshiN., and ShenkT. (1996). Oncogenic potential of the adenovirus E4orf6 protein. Proc. Natl. Acad. Sci. USA, 93, 11295–11301.
107.
MorseM.A., ChaudhryA., GabitzschE.S., et al. (2013). Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol. Immunother., 62, 1293–1301.
108.
NalbantogluJ., PariG., KarpatiG., and HollandP.C. (1999). Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum. Gene Ther., 10, 1009–1019.
109.
NilssonE.C., StormR.J., BauerJ., et al. (2011). The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis. Nat. Med., 17, 105–109.
110.
NociariM., OcheretinaO., SchogginsJ.W., and Falck-PedersenE. (2007). Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J. Virol., 81, 4145–4157.
111.
OgwangC., AfolabiM., KimaniD., et al. (2013). Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One, 8, e57726.
112.
O'HaraG.A., DuncanC.J., EwerK.J., et al. (2012). Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis., 205, 772–781.
113.
OliveM., EisenlohrL., FlomenbergN., et al. (2002). The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum. Gene Ther., 13, 1167–1178.
114.
OnionD., CromptonL.J., MilliganD.W., et al. (2007). The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein. J. Gen. Virol., 88, 2417–2425.
115.
OuedraogoA., TionoA.B., KargougouD., et al. (2013). A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One, 8, e78679.
116.
Penaloza-MacmasterP., ProvineN.M., RaJ., et al. (2013). Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J. Virol., 87, 1373–1384.
117.
PerreauM., PantaleoG., and KremerE.J. (2008). Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J. Exp. Med., 205, 2717–2725.
118.
PesonenS., DiaconuI., KangasniemiL., et al. (2012). Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res., 72, 1621–1631.
119.
PetersW., BrandlJ.R., LindbloomJ.D., et al. (2013). Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine, 31, 1752–1758.
120.
Pichla-GollonS.L., DrinkerM., ZhouX., et al. (2007). Structure-based identification of a major neutralizing site in an adenovirus hexon. J. Virol., 81, 1680–1689.
121.
PintoA.R., FitzgeraldJ.C., Giles-DavisW., et al. (2003). Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J. Immunol., 171, 6774–6779.
122.
RadosevicK., RodriguezA., LemckertA.A., et al. (2010). The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin. Vaccine Immunol., 17, 1687–1694.
123.
RameshN., GeY., EnnistD.L., et al. (2006). CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res., 12, 305–313.
124.
RestifoN.P. (2001). Hierarchy, tolerance, and dominance in the antitumor T-cell response. J. Immunother., 24, 193–194.
125.
RichardsonJ.S., PilletS., BelloA.J., and KobingerG.P. (2013). Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J. Virol., 87, 3668–3677.
RobinsonC.M., SinghG., HenquellC., et al. (2011). Computational analysis and identification of an emergent human adenovirus pathogen implicated in a respiratory fatality. Virology, 409, 141–147.
128.
RockK.L., and ShenL. (2005). Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev., 207, 166–183.
129.
RoelvinkP.W., LizonovaA., LeeJ.G., et al. (1998). The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol., 72, 7909–7915.
130.
RoweW.P. (1953). Propagation of group A Coxsackie viruses in denervated adult mouse muscle. Science, 117, 710.
131.
RoyS., ShirleyP.S., McclellandA., and KalekoM. (1998). Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol., 72, 6875–6879.
RuxJ.J., KuserP.R., and BurnettR.M. (2003). Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J. Virol., 77, 9553–9566.
134.
SabanS.D., SilvestryM., NemerowG.R., and StewartP.L. (2006). Visualization of alpha-helices in a 6-angstrom resolution cryoelectron microscopy structure of adenovirus allows refinement of capsid protein assignments. J. Virol., 80, 12049–12059.
135.
SachsM.D., RauenK.A., RamamurthyM., et al. (2002). Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology, 60, 531–536.
136.
SafronetzD., HegdeN.R., EbiharaH., et al. (2009). Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus. J. Virol., 83, 7285–7295.
137.
SangroB., MazzoliniG., RuizJ., et al. (2004). Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol., 22, 1389–1397.
138.
SchirmbeckR., ReimannJ., KochanekS., and KreppelF. (2008). The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol. Ther., 16, 1609–1616.
139.
SchultzE.S., LetheB., CambiasoC.L., et al. (2000). A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res., 60, 6272–6275.
140.
SereginS.S., AldhamenY.A., RastallD.P., et al. (2012). Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine, 30, 1492–1501.
141.
SharmaA., TandonM., AhiY.S., et al. (2010). Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther., 17, 634–642.
142.
ShayakhmetovD.M., and LieberA. (2000). Dependence of adenovirus infectivity on length of the fiber shaft domain. J. Virol., 74, 10274–10286.
143.
SheehyS.H., DuncanC.J., EliasS.C., et al. (2012a). Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One, 7, e31208.
144.
SheehyS.H., DuncanC.J., EliasS.C., et al. (2012b). ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther., 20, 2355–2368.
145.
ShinS.P., SeoH.H., ShinJ.H., et al. (2013). Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. Mol. Ther., 21, 688–695.
146.
SinghN., PandeyA., JayashankarL., and MittalS.K. (2008). Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol. Ther., 16, 965–971.
147.
SinnP.L., WilliamsG., VongpunsawadS., et al. (2002). Measles virus preferentially transduces the basolateral surface of well-differentiated human airway epithelia. J. Virol., 76, 2403–2409.
148.
SmaillF., JeyanathanM., SmiejaM., et al. (2013). A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci. Transl. Med., 5, 205ra134.
149.
SmithC., TsangJ., BeagleyL., et al. (2012). Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res., 72, 1116–1125.
150.
StewartP.L., FullerS.D., and BurnettR.M. (1993). Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J., 12, 2589–2599.
151.
StrunzeS., EngelkeM.F., WangI.H., et al. (2011). Kinesin-1-mediated capsid disassembly and disruption of the nuclear pore complex promote virus infection. Cell Host Microbe, 10, 210–223.
152.
SulemanM., GaleaS., GavardF., et al. (2011). Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8alpha+dendritic cell subset. Vaccine, 29, 5892–5903.
153.
SundararajanR., CuconatiA., NelsonD., and WhiteE. (2001). Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J. Biol. Chem., 276, 45120–45127.
154.
SungR.S., QinL., and BrombergJ.S. (2001). TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression. Mol. Ther., 3, 757–767.
155.
TamaniniA., NicolisE., and BonizzatoA., et al. (2006). Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J. Virol., 80, 11241–11254.
156.
TatsisN., TesemaL., RobinsonE.R., et al. (2006). Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther., 13, 421–429.
157.
TeiglerJ.E., IampietroM.J., and BarouchD.H. (2012). Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J. Virol., 86, 9590–9598.
158.
ThornerA.R., LemckertA.A., GoudsmitJ., et al. (2006). Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J. Virol., 80, 12009–12016.
159.
TodorovaK., IgnatovaI., TchakarovS., et al. (2005). Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun., 5, 1.
160.
TongA.W., NemunaitisJ., SuD., et al. (2005). Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol. Ther., 11, 160–172.
161.
TrotmanL.C., MosbergerN., FornerodM., et al. (2001). Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat. Cell Biol., 3, 1092–1100.
162.
TuettenbergA., JonuleitH., TutingT., et al. (2003). Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy. Gene Ther., 10, 243–250.
163.
Van KampenK.R., ShiZ., GaoP., et al. (2005). Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine, 23, 1029–1036.
164.
Van RaaijM.J., LouisN., ChroboczekJ., and CusackS. (1999). Structure of the human adenovirus serotype 2 fiber head domain at 1.5 A resolution. Virology, 262, 333–343.
165.
VemulaS.V., AhiY.S., SwaimA.M., et al. (2013). Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS One, 8, e62496.
166.
VogelsR., ZuijdgeestD., Van RijnsoeverR., et al. (2003). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol., 77, 8263–8271.
WalshM.P., SetoJ., LiuE.B., et al. (2011). Computational analysis of two species C human adenoviruses provides evidence of a novel virus. J. Clin. Microbiol., 49, 3482–3490.
169.
WaltersR.W., GrunstT., BergelsonJ.M., et al. (1999). Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J. Biol. Chem., 274, 10219–10226.
170.
WangH., LiZ.Y., LiuY., et al. (2011). Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat. Med., 17, 96–104.
171.
WeaverE.A., and BarryM.A. (2013). Low seroprevalent species D adenovirus vectors as influenza vaccines. PLoS One, 8, e73313.
172.
WeaverE.A., NeheteP.N., NeheteB.P., et al. (2013). Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS One, 8, e67574.
173.
WohlfartC. (1988). Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol., 62, 2321–2328.
174.
WortmannA., VohringerS., EnglerT., et al. (2008). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther., 16, 154–162.
175.
WuE., PacheL., Von SeggernD.J., et al. (2003). Flexibility of the adenovirus fiber is required for efficient receptor interaction. J. Virol., 77, 7225–7235.
176.
XiaD., HenryL.J., GerardR.D., and DeisenhoferJ. (1994). Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure, 2, 1259–1270.
177.
XiangZ., LiY., CunA., et al. (2006). Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis., 12, 1596–1599.
178.
XuZ., QiuQ., TianJ., et al. (2013). Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat. Med., 19, 452–457.
179.
YamasakiS., MiuraY., DavydovaJ., et al. (2013). Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer. Int. J. Cancer, 133, 88–97.
180.
YangT.C., DayballK., WanY.H., and BramsonJ. (2003). Detailed analysis of the CD8+ T-cell response following adenovirus vaccination. J. Virol., 77, 13407–13411.
181.
YouilR., TonerT.J., SuQ., et al. (2002). Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther., 13, 311–320.
182.
YousufM.A., ZhouX., and MukherjeeS., et al. (2013). Caveolin-1 associated adenovirus entry into human corneal cells. PLoS One, 8, e77462.
183.
ZahnR., GillisenG., RoosA., et al. (2012). Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One, 7, e44115.
184.
ZandvlietM.L., FalkenburgJ.H., Van LiemptE., et al. (2010). Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica, 95, 1943–1951.
185.
ZhangS.-N., ChoiI.-K., HuangJ.-H., et al. (2011). Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol. Ther., 19, 1558–1568.
186.
ZhangJ., JexE., FengT., et al. (2013a). An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen. Clin. Vaccine Immunol., 20, 1–8
187.
ZhangS., HuangW., ZhouX., et al. (2013b). Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J. Med. Virol., 85, 1077–1084
188.
ZhouD., WuT.L., EmmerK.L., et al. (2013). Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus. Mol. Ther., 21, 696–706.
189.
ZhuJ., HuangX., and YangY. (2007). Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol., 81, 3170–3180.
190.
ZubietaC., SchoehnG., ChroboczekJ., and CusackS. (2005). The structure of the human adenovirus 2 penton. Mol. Cell, 17, 121–135.
